Comparative Pharmacology
Head-to-head clinical analysis: PRINCIPEN versus PRINCIPEN 125.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PRINCIPEN versus PRINCIPEN 125.
PRINCIPEN vs PRINCIPEN '125'
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ampicillin, a beta-lactam antibiotic, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) and interfering with transpeptidation, leading to cell lysis.
Ampicillin is a penicillin beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, leading to cell lysis.
250-500 mg orally every 6 hours or 500 mg intravenously every 6 hours for moderate infections; severe infections: 500 mg-1 g every 4-6 hours.
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg to 1 g every 6 hours for severe infections.
None Documented
None Documented
0.5–1 hour; prolonged to 7–10 hours in renal impairment (creatinine clearance <10 mL/min).
Terminal elimination half-life: 0.7-1.4 hours in adults with normal renal function. Prolonged in renal impairment (up to 7-10 hours in anuria).
Primarily renal (90–100% unchanged) via tubular secretion and glomerular filtration. Minor biliary excretion (<1%).
Renal: approximately 60-80% of the dose excreted unchanged in urine via tubular secretion and glomerular filtration. Biliary/fecal: minimal, <10%.
Category C
Category C
Aminopenicillin Antibiotic
Aminopenicillin Antibiotic